综合基因组分析 (CGP) 可以识别许多目标。然而，报销决策具有挑战性，因为除了标签治疗的健康益处和成本之外，与诊断和治疗途径相关的其他因素也可能发挥作用。本研究的目的是确定哪些其他因素与 CGP 技术评估相关，并总结这些因素的现有证据。经过范围搜索和两次专家会议后，确定了五个因素：可行性、测试过程、诊断结果的更广泛影响、实验室的组织和“科学溢出”。随后，系统性检索确定了 83 项研究，主要收集“测试旅程”和“诊断结果的更广泛影响”因素的证据。然而，其性质对于决策的价值有限。我们建议使用比较策略、结果定义的统一性以及在未来证据生成中纳入一套全面的因素。版权所有 © 2024 Elsevier B.V. 保留所有权利。

Comprehensive Genomic Profiling (CGP) allows for the identification of many targets. Reimbursement decision-making is, however, challenging because besides the health benefits of on-label treatments and costs, other factors related to diagnostic and treatment pathways may also play a role. The aim of this study was to identify which other factors are relevant for the technology assessment of CGP and to summarize the available evidence for these factors. After a scoping search and two expert sessions, five factors were identified: feasibility, test journey, wider implications of diagnostic results, organisation of laboratories, and "scientific spillover". Subsequently, a systematic search identified 83 studies collecting mainly evidence for the factors "test journey" and "wider implications of diagnostic results". Its nature was, however, of limited value for decision-making. We recommend the use of comparative strategies, uniformity in outcome definitions, and the inclusion of a comprehensive set of factors in future evidence generation.Copyright © 2024 Elsevier B.V. All rights reserved.